Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Microscopic Polyangiitis (MPA) - Overview Microscopic Polyangiitis (MPA) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Microscopic Polyangiitis (MPA) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development Celltrion Inc ChemoCentryx Inc InflaRx NV Teijin Pharma Ltd Microscopic Polyangiitis (MPA) - Drug Profiles avacopan - Drug Profile Product Description Mechanism Of Action R&D Progress IFX-1 - Drug Profile Product Description Mechanism Of Action R&D Progress immune globulin (human) - Drug Profile Product Description Mechanism Of Action R&D Progress rituximab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress rituximab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress Microscopic Polyangiitis (MPA) - Dormant Projects Microscopic Polyangiitis (MPA) - Discontinued Products Microscopic Polyangiitis (MPA) - Product Development Milestones Featured News & Press Releases May 18, 2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab) Dec 15, 2016: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Truxima Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Number of Products by Stage and Target, H1 2019 Number of Products by Stage and Mechanism of Action, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Microscopic Polyangiitis (MPA) - Pipeline by Celltrion Inc, H1 2019 Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx Inc, H1 2019 Microscopic Polyangiitis (MPA) - Pipeline by InflaRx NV, H1 2019 Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Ltd, H1 2019 Microscopic Polyangiitis (MPA) - Dormant Projects, H1 2019 Microscopic Polyangiitis (MPA) - Discontinued Products, H1 2019List of Figures Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019 6 Number of Products under Development by Companies, H1 2019 7 Number of Products by Top 10 Targets, H1 2019 9 Number of Products by Stage and Targets, H1 2019 9 Number of Products by Mechanism of Actions, H1 2019 11 Number of Products by Stage and Mechanism of Actions, H1 2019 11 Number of Products by Routes of Administration, H1 2019 13 Number of Products by Stage and Routes of Administration, H1 2019 13 Number of Products by Molecule Types, H1 2019 15 Number of Products by Stage and Molecule Types, H1 2019 15

Celltrion Inc ChemoCentryx Inc InflaRx NV Teijin Pharma Ltd